Only eight percent of CNS drugs will reach approval, in part because of the high adverse effects standards.
Pierre Geoffroy
Advertisement
Articles by Pierre Geoffroy
Advertisement
Latest Updated Articles
CNS Drug Liabilities in Early Phase Clinical TrialsPublished: May 1st 2013 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Honing the Power of AI for Next Generation Trial Oversight and Execution
2
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
3
Verzenio and Kisqali Deliver Positive Long-Term Results in Early Breast Cancer Trials
4
Accelerating Development Through Parallel Execution and Rigorous Quality Controls
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
